Loading
UCART22 is an experimental allogeneic CAR T-cell therapy from Cellectis S.A. in phase 2 trials for acute lymphoblastic leukaemia, aimed at CD22.
UCART22 is an allogeneic CAR T-cell therapy developed by Cellectis S.A.. Its target is CD22. The sponsor states: Gene-edited, donor-derived T cells engineered to recognise and attack CD22-positive leukaemia cells. ClinicalTrials.gov describes the intervention as: Allogeneic engineered T-cells expressing anti-CD22 Chimeric Antigen Receptor given following a lymphodepleting regimen. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in acute lymphoblastic leukaemia. The largest, NCT04150497, plans to enrol 52 participants with primary completion was scheduled for 2026-06-30 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Gene-edited, donor-derived T cells engineered to recognise and attack CD22-positive leukaemia cells. Connects to CD22.
1.UCART22 slips into a pocket on CD22.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"UCART22" OR ABSTRACT:"UCART22") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about UCART22, not a curated reading list.
Shares CD22 and the tag pipeline.
Shares Acute lymphoblastic leukaemia and the tag pipeline.
Shares Acute lymphoblastic leukaemia and the tag pipeline.
Shares Acute lymphoblastic leukaemia and the tag pipeline.
Shares Acute lymphoblastic leukaemia and the tag pipeline.
Shares Acute lymphoblastic leukaemia and the tag pipeline.
Shares Acute lymphoblastic leukaemia and the tag pipeline.
Shares Acute lymphoblastic leukaemia and the tag pipeline.